Optime Care Partners with Pharmaceutical Manufacturers to Deliver a Full Suite of Integrated Pre-Commercialization, Patient Management and HUB Services

Enhanced Partnership with Rigel Pharmaceuticals, Inc. for Rezlidhia™ Patients.
· 8 min read

When looking for a single-source partner with expertise in the launch and management of rare/orphan disease products while ensuring specialty and rare disease patients receive the best care possible for optimal treatment and clinical outcomes, pharmaceutical manufacturers choose Optime Care.

Optime Care’s comprehensive suite of services includes pre-commercialization and market access expertise, exclusive distribution partnerships, national medication fulfillment and high-touch patient support and HUB services such as patient intake, prior authorization support and custom clinical programs with interventions at key points in therapy to increase compliance.

Optime Care takes a patient-first, collaborative approach to the management of rare disease patients and works together with pharmaceutical manufacturers to develop personalized care programs to ensure that patients have seamless access to medications and obtain maximum benefits from therapies prescribed, resulting in enhanced clinical outcomes.

To learn more, click here.

Loading cookie banner...